|
|
Regen Therapeutics PLC - Comparative Business Analysis Snapshot
Business Description
Regen Therapeutics PLC. The Group's principal activities are developing healthcare products both nutraceutical and ethical pharmaceuticals and conducting pharmacokinetic and pharmacodynamic research. Its operation focuses on the research and development of a drug product called Colostrinin for the treatment for Alzheimer's disease and other neurological disorders. Colostrinin is a proline-rich polypeptide complex derived from ovine and bovine colostrum. The Group operates solely in the United Kingdom.
Competitor Analysis
This analysis compares Regen Therapeutics PLC with three other companies in closely related industry sectors.
The full Comparative Business Report is available to Subscribers or may be purchased individually. The full report generally includes the following sections:
- Sales Analysis: Recent Sales, Sales Growth, Sales per Employee
- Recent Stock Performance
- Company Valuation Ratios: Price/Earnings, Price/Book Value
- Price/Sales and 52 Week Price change
- Dividend Analysis
- Profitability Analysis: Gross Profit Margin, EBITDA Margin
- Earnings Before Extraordinary Items
- Inventory Analysis
- Research and Development Expenses
- Financial Position: Long Term Debt/Equity, Days Accounts Receivable, Days Inventory
- R&D Expenses/Sales
Not the Report you are looking for? Click here for more browsing options.
|
|
|
|
|
